EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Interval Cytoreductive Surgery and Cisplatin- or Paclitaxel-Based HIPEC for Advanced Ovarian Cancer

Salud González Sánchez, Jorge García Fernández, Pedro Antonio Cascales-Campos, Alida Gonzalez Gil, Israel Manzanedo, Fernando Pereira Perez, Daniel Díaz Gómez, Carlos González-de Pedro, Enrique Asensio Diaz, David Pacheco Sanchez, Aranzazu Prada-Villaverde, Isabel Jaén Torrejimeno und 24 weitere

JAMA Network Open · 26.06.2025 · 8 (6) · e2517676

DOI: 10.1001/jamanetworkopen.2025.17676 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Network Open, online erschienen am 26.06.2025. Verfasst von Salud González Sánchez und 35 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Surgical Oncology, Reina Sofia University Hospital, Cordoba, Spain. Hauptthemen laut MEDLINE: Paclitaxel, Cisplatin, Ovarian Neoplasms, Cytoreduction Surgical Procedures. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Ovarian cancer, often diagnosed at advanced stages, presents significant challenges in treatment and survival. Evaluation of different hyperthermic intraperitoneal chemotherapy (HIPEC) regimens could provide crucial insights to improve patient outcomes.

Objective

To evaluate whether HIPEC with paclitaxel (HIPEC-paclitaxel) is associated with similar oncological outcomes as HIPEC with cisplatin (HIPEC-cisplatin) in patients with advanced ovarian cancer undergoing interval cytoreductive surgery (iCRS). Design, Setting, and Participants This multicenter retrospective cohort study included patients with advanced ovarian cancer who received iCRS and HIPEC. Patients with primary or secondary surgical procedures or nonovarian cancers were excluded. Data came from the National Registry of Peritoneal Carcinomatosis, which includes 27 Spanish specialized peritoneal oncology centers. Cases were included from January 2012 to December 2022. The study used propensity score matching to balance the groups and ensure comparability. Exposure HIPEC-cisplatin and HIPEC-paclitaxel, administered during iCRS. The HIPEC regimen was selected based on the standard clinical protocol for advanced ovarian cancer. Main Outcomes and Measures The primary end points were overall survival (OS) and disease-free survival (DFS). The secondary end point was the rate of complications in each group. These outcomes were predefined prior to data collection.

Results

A total of 846 patients (mean [SD] age, 59.04 [11.01] years) were included (325 [38.4%] in HIPEC-cisplatin group; 521 [61.6%] in HIPEC-paclitaxel group), and 199 patients in each group were propensity score matched. Among these 398 matched patients, the HIPEC-paclitaxel group had similar DFS and OS compared with the HIPEC-cisplatin group. Additionally, similar morbidity was observed. Equivalence in OS and DFS was observed during the initial 20 and 15 months of follow-up, respectively, with an equivalence margin of 0.1 respectively. Conclusions and Relevance In this cohort study of patients with advanced ovarian cancer, HIPEC-paclitaxel was associated with comparable oncologic outcomes as HIPEC-cisplatin, suggesting that it could be a viable alternative. These findings support its use, especially in patients in whom cisplatin could be contraindicated. Further studies may help refine treatment protocols and improve patient-specific outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelCisplatinOvarian NeoplasmsCytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyAntineoplastic AgentsHumansFemaleMiddle AgedRetrospective StudiesAgedAdultTreatment Outcome

Substanzen

PaclitaxelCisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Unit of Surgical Oncology, Reina Sofia University Hospital, Cordoba, Spain.
  • GE09 Research in Peritoneal and Retroperitoneal Oncologic Surgery Group, Maimonides Biomedical Research Institute of Cordoba, Reina Sofía University Hospital, University of Cordoba, Córdoba, Spain.
  • Unit of Gynecology, Reina Sofia University Hospital, Cordoba, Spain.
  • Peritoneal Surface Malignancy Unit, Department of Surgery Clinic and University Hospital "Virgen de la Arrixaca," University of Murcia, Murcia, Spain.
  • Peritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, Fuenlabrada University Hospital, Madrid, Spain.
  • Unit of Surgical Oncology Peritoneal and Retroperitoneal, Virgen del Rocio University Hospital, Seville, Spain.

Zitieren

APA

González Sánchez, S., García Fernández, J., Cascales-Campos, P. A., Gonzalez Gil, A., Manzanedo, I., Pereira Perez, F., Díaz Gómez, D., González-de Pedro, C., Asensio Diaz, E., Pacheco Sanchez, D., Prada-Villaverde, A., Jaén Torrejimeno, I., Lacueva, J., Caravaca-Garcia, I., Torres-Melero, J., Sanchez-García, S., Díaz Reques, E., Ramírez Plaza, C., Gutiérrez-Calvo, A., …, & REGECOP collaborators (2025). Interval Cytoreductive Surgery and Cisplatin- or Paclitaxel-Based HIPEC for Advanced Ovarian Cancer. JAMA Network Open, 8(6), e2517676. https://doi.org/10.1001/jamanetworkopen.2025.17676

Vancouver

González Sánchez S, García Fernández J, Cascales-Campos PA, Gonzalez Gil A, Manzanedo I, Pereira Perez F, et al. Interval Cytoreductive Surgery and Cisplatin- or Paclitaxel-Based HIPEC for Advanced Ovarian Cancer. JAMA Network Open. 2025;8(6):e2517676. doi:10.1001/jamanetworkopen.2025.17676

BibTeX
@article{GonzlezSnchez2025,
  author = {González Sánchez, Salud and García Fernández, Jorge and Cascales-Campos, Pedro Antonio and Gonzalez Gil, Alida and Manzanedo, Israel and Pereira Perez, Fernando and Díaz Gómez, Daniel and González-de Pedro, Carlos and Asensio Diaz, Enrique and Pacheco Sanchez, David and Prada-Villaverde, Aranzazu and Jaén Torrejimeno, Isabel and Lacueva, Javier and Caravaca-Garcia, Iban and Torres-Melero, Juan and Sanchez-García, Susana and Díaz Reques, Eduardo and Ramírez Plaza, César and Gutiérrez-Calvo, Alberto and González Bayón, Luis and Morales-Soriano, Rafael and López-Mozos, Fernando and Bjelic, Lana and Galindo Álvarez, Julio and Marcello Fernandez, Manuel Emilio and Turienzo Santos, Estrella and Titos García, Alberto and Álvarez Seoane, Rosa and Artiles Armas, Manuel and Garaulet, Emilio Terol and Villarejo Campos, Pedro and Boldó Roda, Enrique and Rihuete Caro, Cristina and García Fadrique, Alfonso and Arjona-Sánchez, Álvaro and REGECOP collaborators, REGECOP collaborators},
  title = {Interval Cytoreductive Surgery and Cisplatin- or Paclitaxel-Based HIPEC for Advanced Ovarian Cancer},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {6},
  pages = {e2517676},
  doi = {10.1001/jamanetworkopen.2025.17676}
}
Kostenlos starten →